
(IN BRIEF) The Institute of Cancer Research, London, has published two major studies demonstrating how pairing a cancer-killing reovirus with targeted therapies such as talazoparib and palbociclib can greatly strengthen immune activity and tumour destruction. By disrupting cancer cell defences … Read the full press release